Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$144.31

0.08 (0.06%)

, CLVS

Clovis

$59.97

0.27 (0.45%)

09:45
06/19/17
06/19
09:45
06/19/17
09:45

Raymond James remains cautious on Tesaro, takeout less likely

Raymond James analyst Christopher Raymond remains cautious on Tesaro (TSRO) shares following Clovis' (CLVS) Rubraca ARIEL3 results. The analyst said PFS measures between the Clovis Rubraca and Tesaro's Zejula are remarkably similar among ovarian cancer patients, making the PARP space much more competitive and crowded. Raymond believes a takeout of Tesaro based on Zejula's superior labeling is much less likely and reiterated his Market Perform rating on shares.

TSRO

Tesaro

$144.31

0.08 (0.06%)

CLVS

Clovis

$59.97

0.27 (0.45%)

  • 30

    Jun

TSRO Tesaro
$144.31

0.08 (0.06%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/16/17
FBCO
06/16/17
NO CHANGE
Target $88
FBCO
Outperform
Clovis price target raised to $88 from $74 at Credit Suisse
Credit Suisse analyst Alethia Young assumed coverage of Clovis Oncology (CLVS) and raised the firm's price target on the stock to $88 from $74, noting that her 2023 U.S. estimate for rucaparib is $1.3B versus prior coverage's forecast of $700M. Young, who thinks that the PARPi market is big enough that both Clovis and Tesaro (TSRO) can have blockbuster products, believes both companies are likely attractive targets for large global pharma companies, she tells investors. The analyst keeps an Outperform rating on Clovis shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Outperform
Clovis should now be 'prime takeout candidate,' says Leerink
Leerink analyst Michael Schmidt views this morning's data from Clovis Oncology (CLVS) as the "best-case outcome." The data indicate that efficacy of the three leading PARP inhibitors look very comparable, Schmidt tells investors in a research note titled "Bull Case Plays Out as ARIEL3 Hits All Endpoints." Tesaro (TSRO) and AstraZeneca (AZN) own the other leading PARP inhibitors. The analyst expects shares of Clovis to "trade up significantly" on today's news. Clovis shares in premarket trading are up 40%, or $24.03, to $84.00. "With best-case data in hand," Clovis should be a "prime takeout candidate," Schmidt tells investors. He reiterates an Outperform rating on the shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Market Perform
Clovis reported similar efficacy to Tesaro's Zejula, says Leerink
Leerink analyst Seamus Fernandez says the top-line efficacy data announced this morning for Clovis Oncology's (CLVS) Phase 3 Ariel3 trial of its PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's (TSRO) Nova trial of Zejula across all patient population in second-line or greater ovarian cancer maintenance. This adds "considerable weight" to the argument that all three of these PARP inhibitors have similar activity, Fernandez tells investors in a research note. The analyst keeps a Market Perform rating on Tesaro shares.
CLVS Clovis
$59.97

0.27 (0.45%)

06/19/17
CHDN
06/19/17
UPGRADE
CHDN
Neutral
Clovis upgraded to Neutral from Sell at Chardan
06/19/17
STFL
06/19/17
NO CHANGE
Target $125
STFL
Buy
Clovis price target raised to $125 from $86 at Stifel

TODAY'S FREE FLY STORIES

ISBC

Investors Bancorp

$13.41

0.12 (0.90%)

07:49
09/19/17
09/19
07:49
09/19/17
07:49
Conference/Events
Investors Bancorp management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

TGS

Transportadora de Gas del Sur SA

$17.48

0.07 (0.40%)

07:49
09/19/17
09/19
07:49
09/19/17
07:49
Initiation
Transportadora de Gas del Sur SA initiated  »

Transportadora de Gas del…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAM

Pampa Energia S.A.

$60.93

0.2 (0.33%)

07:48
09/19/17
09/19
07:48
09/19/17
07:48
Initiation
Pampa Energia S.A. initiated  »

Pampa Energia S.A. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Progress Software »

Progress:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Progress Software 'values' Praesidium's ideas, welcomes input from investors »

In response to a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

, AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Hot Stocks
Jacobs Engineering selected by Aerie Pharmaceuticals as engineering contractor »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

, AXAHY

AXA

$29.47

0.13 (0.44%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Periodicals
BNP weighing tie-up of money-management division with Axa unit, Bloomberg says »

BNP Paribas (BNPQY),…

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

AXAHY

AXA

$29.47

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSII

Quality Systems

$15.71

-0.14 (-0.88%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Initiation
Quality Systems initiated  »

Quality Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/19/17
09/19
07:45
09/19/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: Risk-on…

HOLI

Hollysys

$20.77

0.42 (2.06%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Conference/Events
Hollysys management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

, AMGN

Amgen

$186.47

-1 (-0.53%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Hot Stocks
Cytokinetics doses first patient in Japan in GALACTIC-HF Phase 3 trial »

Cytokinetics announced…

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

AMGN

Amgen

$186.47

-1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

KORS

Michael Kors

$44.65

-0.27 (-0.60%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Technical Analysis
Technical View: Michael Kors moves higher, analyst action »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Periodicals
Intel Capital invested over $1B in AI-focused companies, TechCrunch says »

Intel has invested more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 05

    Oct

PDCO

Patterson Companies

$37.94

-0.59 (-1.53%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Initiation
Patterson Companies initiated  »

Patterson Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$179.98

3.28 (1.86%)

, BSTI

BEST Inc

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Syndicate
BEST Inc cuts size of proposed IPO following 'tepid' response, Reuters reports »

Best Inc (BSTI), a…

BABA

Alibaba

$179.98

3.28 (1.86%)

BSTI

BEST Inc

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FOLD

Amicus

$13.67

-0.21 (-1.51%)

07:42
09/19/17
09/19
07:42
09/19/17
07:42
Hot Stocks
Amicus granted FDA Fast Track Designation for migalastat »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.73

0.1 (3.80%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Initiation
Rite Aid initiated  »

Rite Aid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MDGL

Madrigal Pharmaceuticals

$19.80

0.99 (5.26%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Hot Stocks
Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB review »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MDSO

Medidata

$75.85

-0.01 (-0.01%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Initiation
Medidata initiated  »

Medidata initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ABX

Barrick Gold

$16.92

-0.38 (-2.20%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Conference/Events
Barrick Gold management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Oct

07:40
09/19/17
09/19
07:40
09/19/17
07:40
General news
Treasury Market Outlook: yields are a little lower »

Treasury Market Outlook:…

SFTBF

SoftBank

$78.30

0.3501 (0.45%)

07:39
09/19/17
09/19
07:39
09/19/17
07:39
Periodicals
SoftBank Ventures Korea looks to invest in promising start-ups, CNBC says »

SoftBank Ventures Korea,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.42

-1.46 (-0.97%)

07:38
09/19/17
09/19
07:38
09/19/17
07:38
Initiation
McKesson initiated  »

McKesson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

SUPN

Supernus

$49.65

0.6 (1.22%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Downgrade
Supernus rating change  »

Supernus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.